RTOG 97-06: Initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy

International Journal of Radiation Oncology Biology Physics

Volumn 57, Issue 3, 2003, Pages 665-672

  Hagan, Michael P ^a   Winter, Kathryn A ^b   Kaufman, Donald S ^c   Wajsman, Zev ^d   Zietman, Anthony L ^c   Heney, Naill M ^c   Toonkel, Leonard M ^e   Jones, Christopher U ^f   Roberts, John D ^a   Shipley, William U ^c  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RADIATION THERAPY ONCOLOGY GROUP   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

^e MOUNT SINAI MEDICAL CENTER   (United States)

^f Radiological Associates of Sacramento Medical Group Inc   (United States)

Author keywords

Bladder cancer; Bladder conservation; Chemotherapy; Radiotherapy

Indexed keywords

CHEMOTHERAPY; IRRADIATION; PATHOLOGY; TOXICITY; TUMORS;

INDUCTION TREATMENT;

ONCOLOGY;

CISPLATIN; METHOTREXATE; VINBLASTINE;

ADULT; AGED; ARTICLE; BLADDER TUMOR; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTECTOMY; CYSTOSCOPY; CYTODIAGNOSIS; CYTOLOGY; DISEASE SEVERITY; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HEMATURIA; HUMAN; HYDRONEPHROSIS; INFECTION; INSTITUTIONAL CARE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PATIENT ATTITUDE; PATIENT SELECTION; PELVIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RADIOSENSITIZATION; SCORING SYSTEM; SENSITIZATION; STATISTICAL MODEL; THROMBOCYTOPENIA; TOXICITY; TRANSURETHRAL RESECTION; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR BIOPSY; VOMITING;

EID: 0141615695     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(03)00718-1     Document Type: Article

References (26)

1. Shipley W.U., Zietman A.L., Kaufman D.S., et al. Invasive bladder cancer Treatment strategies using transurethral surgery, chemotherapy and radiation therapy with selection for bladder conservation . Int J Radiat Oncol Biol Phys. 39:1997;937-943.
2. Shipley W.U., Kaufman D.S., Zehr E., et al. Selective bladder preservation by combined modality protocol treatment Long-term outcomes of 190 patients with invasive bladder cancer . Urology. 60:2002;62-67.
3. Sauer R., Birkenhake S., Kuhn R., et al. Efficacy of radiochemotherapy with platin derivatives compared to radiotherapy alone in organ sparing treatment of bladder cancer. Int J Radiat Oncol Biol Phys. 40:1998;121-127.
4. Housset M., Maulard C., Chretien Y., et al. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder A prospective study . J Clin Oncol. 11:1993;2150-2157.
5. Tester W., Porter A., Asbell S., et al. Combined modality program with possible organ preservation for invasive bladder carcinoma Results of RTOG protocol 85-12 . Int J Radiat Oncol Biol Phys. 25:1993;783-790.
6. Tester W., Caplan R., Heaney J., et al. Neoadjuvant combined modality therapy with possible organ preservation for invasive bladder cancer. J Clin Oncol. 14:1996;119-126.
7. Shipley W.U., Winter K.A., Kaufman D.S., et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation and chemotherapy Initial results of Radiation Therapy Oncology Group 89-03 . J Clin Oncol. 16:1998;3576-3583.
8. Kaufman D.S., Winter K.A., Shipley W.U., et al. The initial results in muscle-invading bladder cancer of RTOG 95-06 Phase I-II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective preservation or cystectomy depending on the initial response . Oncologist. 5:2000;471-476.
9. Shipley W.U., Prout G.R. Jr, Einstein A.B., et al. Treatment of invasive bladder cancer by cisplatin and radiation in patients unsuited for surgery. JAMA. 258:1987;931-935.
10. Maciejewski B., Majewski S. Dose fractionation and tumor repopulation in radiotherapy for bladder cancer. Radiother Oncol. 21:1991;163-170.
11. De Neve W., Lybeert M.L., Goor C., et al. Radiotherapy for T2 and T3 carcinoma of the bladder The influence of overall treatment time . Radiother Oncol. 36:1995;183-188.
12. Karnofsky D.A., Burchenal J.H. The clinical evaluation of chemotherapeutic agents in cancer. MacLeod C.M. Evaluation of chemotherapeutic agents. 1949;191-205 Columbia University Press, New York.
13. Kachnic L.A., Kaufman D.S., Heney N.M., et al. Bladder preservation by combined modality therapy for invasive bladder cancer. J Clin Oncol. 15:1997;1022-1029.
14. Chauvet B., Brewer Y., Felix-Faure C., et al. Concurrent cisplatin and radiotherapy for patients with muscle invasive bladder cancer who are not candidates for radical cystectomy. J Urol. 156:1996;1258-1262.
15. Russell K.J., Boileau M.A., Higano C., et al. Combined 5-fluorouracil and irradiation for transitional cell carcinoma of the urinary bladder. Int J Radiat Oncol Biol Phys. 19:1990;693-699.
16. Eapen L., Stewart D., Danjoux C., et al. Intraarterial cisplatin and concurrent radiation for locally advanced bladder cancer. J Clin Oncol. 7:1989;230-235.
17. Wallace D.M., Bloom J.G. The management of deeply infiltrating (T3) bladder carcinoma Controlled trial of radical radiotherapy versus preoperative radiotherapy and radical cystectomy . Br J Urol. 48:1976;587-594.
18. Zietman A.L., Shipley W.U., Kaufman D.S., et al. A phase I/II trial of transurethral surgery combined with concurrent cisplatin, 5-fluoruracil and twice daily irradiation followed by selective bladder preservation in operable patients with muscle invading bladder cancer. J Urol. 160:1998;1673-1677.
19. Rodel C., Grabenbauer G.G., Rodel F., et al. Apoptosis, p53, bcl-2, and Ki-67 in invasive bladder carcinoma Possible predictors for response to radiochemotherapy and successful bladder preservation . Int J Radiat Oncol Biol Phys. 46:2000;1213-1221.
20. Tada Y., Wada M., Taguchi K., et al. The association of death-associated protein kinase hypermethylation with early recurrence in superficial bladder cancers. Cancer Res. 62:2002;4048-4053.
21. Nisman B., Barak V., Shapiro A., et al. Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma. Cancer. 94:2002;2914-2922.
22. Lokeshwar V.B., Schroeder G.L., Selzer M.G., et al. Bladder tumor markers for monitoring recurrence and screening comparison of hyaluronic acid-hyaluronidase and BTA-Stat tests. Cancer. 95:2002;61-72.
23. Blanes A., Rubio J., Martinez A., et al. Kinetic profiles by topographic compartments in muscle-invasive transitional cell carcinomas of the bladder Role of TP53 and NF1 genes . Am J Clin Pathol. 118:2002;93-100.
24. Droller M.J. Current concepts of tumor markers in bladder cancer. Urol Clin North Am. 29:2002;229-234.
25. Kragelj B., Jereb B., Kragelj L., et al. Concurrent vinblastine and radiation therapy in bladder cancer. Cancer. 70:1992;2885-2890.
26. Eapen L., Stewart D., Grimard L., et al. Treatment of cancer of the bladder in elderly patients with an intra-arterial chemotherapy and radiotherapy combination 10-year experience . Cancer Radiother. 2:(Suppl. 1):1998;73s-76s.